nd Charger devices, it offers balloons across all size platforms. The company’s peripheral stent technology includes its EPIC self-expanding nitinol stent system, its Carotid WALLSTENT stent system, and its Innova self-expanding stent system. In addition, the company markets its 0.035 inch Rubicon Support Catheter in both the U.S. and Europe. It is conducting a study designed to evaluate the safety and performance of the self-expanding Innova drug-eluting stent system, designed to treat Superficial Femoral Artery (SFA) lesions, along with an additional study on its Eluvia Drug-Eluting Vascular Stent System, which is designed to treat patients with narrowing or blockages in the SFA or proximal popliteal artery, a result of peripheral artery disease. In August 2014, the company acquired the Interventional Division of Bayer AG (Bayer). The addition of Bayer's strong commercial organization and innovative technologies supports its strategy to provide a portfolio of solutions to treat peripheral vascular disease. The transaction included the AngioJet Thrombectomy System and the Fetch 2 Aspiration Catheter, which are used in endovascular procedures to remove blood clots from blocked arteries and veins, and the JetStream Atherectomy System, used in a therapy to remove plaque and thrombi from diseased arteries. It also launched the AngioJet ZelanteDVT Thrombectomy Catheter to treat deep vein thrombosis (DVT) in large-diameter upper and lower limb peripheral veins, in the U.S. and Europe. The company also sells products designed to treat patients with non-vascular disease (disease that appears outside the blood system). Its non-vascular suite of products includes biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The company markets its Direxion torqueable microcatheter in both the U.S. and Europe. In addition, the company continues to market its line of interventional oncology product solutions, including the Renegade HI-FLO Fathom microcatheter and guidewire system and Interlock - 35 Fibered IDC and 18 Fibered IDC Occlusion System for peripheral embolization. In December 2015, the company acquired the interventional radiology portfolio of CeloNova Biosciences. The acquisition includes drug-eluting microspheres designed to be loaded with chemotherapy drugs for delivery to cancerous tumors, and spherical embolic products used to treat uterine fibroids and other conditions. Rhythm Management Cardiac Rhythm Management The company develops, manufactures and markets various implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including: Implantable cardioverter defibrillator (ICD) systems, which are used to detect and treat abnormally fast heart rhythms (tachycardia) that could result in sudden cardiac death, including the commercially available subcutaneous implantable cardiac defibrillators (S-ICD), along with implantable transvenous cardiac defibrillators and implantable cardiac resynchronization therapy defibrillator (CRT-D) systems used to treat heart failure. Implantable pacemaker systems which are used to manage slow or irregular heart rhythms (bradycardia), including implantable cardiac resynchronization therapy pacemaker (CRT-P) systems used to treat heart failure. In addition, in most geographies, the company’s implantable device systems include its remote LATITUDE Patient Management System, which enables physicians to monitor device performance remotely, allowing for more frequent monitoring in order to guide treatment decisions. The company markets various lines of ICD’s, including its DYNAGEN EL, DYNAGEN MINI, INOGEN EL and INOGEN MINI. In addition, the company offers its EMBLEM S-ICD system, which affords physicians the ability to treat patients who are at risk for sudden cardiac arrest without touching the heart or invading the vasculature. The company’s EMBLEM S-ICD system offers greater longevity, LATITUDE Patient Management remote monitoring technology and smaller size as compared to the prior generation. It also offers various lines of CRT-D systems, i
boston scientific corp (BSX:New York)
300 Boston Scientific Way
Marlborough, MA 01752
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for BSX.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact BOSTON SCIENTIFIC CORP, please visit www.bostonscientific.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.